Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an
industry leader in exoskeleton technology for medical and
industrial use, today announced that MedTech Breakthrough, an
independent market intelligence organization that recognizes the
top companies, technologies, and products in the global health and
medical technology market, has selected Ekso Bionics® as the winner
of its “Best Healthcare Robotics Company” award in the fourth
annual MedTech Breakthrough Awards program.
Ekso Bionics has been developing exoskeleton solutions to
enhance human mobility, strength, and endurance across medical and
industrial applications for over ten years. The latest additions to
the Company’s medical portfolio include the EksoNR exoskeleton,
which is the next generation EksoGT-- the most clinically used
robotic exoskeleton, and the upgraded EksoPulse platform, an
advanced cloud-based analytics solution that measures and analyzes
progress using EksoNR.
Developed for neurorehabilitation, EksoNR is an intuitive
exoskeleton device that empowers patients recovering from stroke or
other conditions to learn to walk again with a more natural gait.
Ekso Bionics designed EksoNR with new features to help physical
therapists and patients get more out of rehabilitation sessions.
The device is equipped with EksoView, a new touchscreen controller
that allows therapists to adapt assistance to challenge patients
using real-time feedback and perform outcome measures during
use.
During rehabilitation sessions, EksoPulse captures important
measures of patient progress, including the number of steps taken,
the quality of steps, and how much assistance was given to a
patient. An easy-to-use dashboard uniquely allows therapists and
administrators to generate insightful metrics and graphs from the
data to monitor patient progress and adjust care plans, which can
have a positive impact on patient care and recovery.
“We are proud to receive recognition as the ‘Best Healthcare
Robotics Company’ from MedTech Breakthrough. Winning this award is
a testament to our industry-leading, innovative approach and the
hard work of the entire Ekso Bionics team,” said Jack Peurach, CEO
and president of Ekso Bionics. “Ekso Bionics remains committed to
developing the latest exoskeleton advances for rehabilitation to
ensure physical therapists have access to the latest tools to
deliver better patient outcomes and superior care in
neurorehabilitation.”
The mission of the MedTech Breakthrough Awards is to honor
excellence and recognize the innovation, hard work and success in a
range of health and medical technology categories, including
Robotics, Clinical Administration, Telehealth, Patient Engagement,
Electronic Health Records (EHR), mHealth, Medical Devices, Medical
Data and many more. This year’s program attracted more than 3,750
nominations from over 15 countries throughout the world.
“Healthcare robotics is one of the most exciting categories that
we evaluate each year, and Ekso Bionics is well-positioned as a
leader and innovator in the category, with ‘breakthrough’ solutions
like the EksoNR,” said James Johnson, managing director, MedTech
Breakthrough. “Physicians and physical therapists use this advanced
therapeutic option to help patients get back on their feet, quite
literally, supporting re-learning of correct step patterns as they
progress through their continuum of care. The continuing innovation
at Ekso Bionics is an impressive series of technology breakthroughs
and we are thrilled to recognize the entire Ekso team as our ‘Best
Healthcare Robotics Company’ award winner.”
EksoNR is cleared by the U.S. Federal Drug Administration for
stroke and spinal cord injury rehabilitation. The device is also
CE-marked and available in Europe. Utilized by over 270
rehabilitation centers around the world, the Ekso device has helped
patients take more than 120 million steps, while supporting
patients’ hopes of early mobility and independence.
About MedTech Breakthrough Part of Tech
Breakthrough, a leading market intelligence and recognition
platform for global technology innovation and leadership, the
MedTech Breakthrough Awards program is an independent program
devoted to honoring excellence in medical and health related
technology companies, products, services and people. The MedTech
Breakthrough Awards provide a platform for public recognition
around the achievements of breakthrough health and medical
companies and products in categories that include Patient
Engagement, mHealth, Health & Fitness, Clinical Administration,
Healthcare IoT, Medical Data, Healthcare Cybersecurity and more.
For more information visit MedTechBreakthrough.com.
About Ekso Bionics® Ekso Bionics® is
a leading developer of exoskeleton solutions that amplify human
potential by supporting or enhancing strength, endurance and
mobility across medical and industrial applications. Founded in
2005, the Company continues to build upon its industry-leading
expertise to design some of the most cutting-edge, innovative
wearable robots available on the market. Ekso Bionics is the only
exoskeleton company to offer technologies that range from helping
those with paralysis to stand up and walk, to enhancing human
capabilities on job sites across the globe. The Company is
headquartered in the San Francisco Bay Area and is listed on the
Nasdaq Capital Market under the symbol “EKSO.” For more
information,
visit: www.eksobionics.com or follow
@EksoBionics on Twitter.
Forward-Looking Statements Any statements
contained in this press release that do not describe historical
facts may constitute forward-looking statements. Forward-looking
statements may include, without limitation, statements regarding
(i) the potential benefits of the Company’s products and systems,
including the EksoNR, EksoPulse and EksoView, (ii) the performance
or effectiveness of the Company’s products, including the EksoNR,
(iii) the development of latest advances in exoskeleton robotics,
and (iv) the assumptions underlying or relating to any statement
described in clauses (i) through (iii) above. Such forward-looking
statements are not meant to predict or guarantee actual results,
performance, events or circumstances and may not be realized
because they are based upon the Company’s current projections,
plans, objectives, beliefs, expectations, estimates and assumptions
and are subject to a number of risks and uncertainties and other
influences, many of which the Company has no control over. Actual
results and the timing of certain events and circumstances may
differ materially from those described by the forward-looking
statements as a result of these risks and uncertainties. Factors
that may influence or contribute to the inaccuracy of the
forward-looking statements or cause actual results to differ
materially from expected or desired results may include, without
limitation, the Company’s inability to obtain adequate financing or
maintain operating revenues (including as a result of the COVID-19
pandemic) to fund the Company’s operations and necessary to develop
or enhance the Company’s technology, the significant length of time
and resources associated with the development of the Company’s
products, the Company’s failure to achieve broad market acceptance
of the Company’s products, the failure of the Company’s sales and
marketing efforts or of partners to market the Company’s products
effectively, adverse results in future clinical studies of the
Company’s medical device products, the failure to obtain or
maintain patent protection for the Company’s technology, the
failure of the Company to obtain or maintain regulatory approval to
market the Company’s medical devices, disruptions in the Company’s
supply chain due to the outbreak of the COVID-19 virus and other
delays that may result from the COVID-19 pandemic, the Company’s
lack of product diversification, existing or increased competition,
and the Company’s failure to implement the Company’s business plans
or strategies. These and other factors are identified and described
in more detail in the Company’s filings with the U.S. Securities
and Exchange Commission. To learn more about Ekso Bionics please
visit the Company’s website at www.eksobionics.com or follow
@EksoBionics on Twitter. The Company does not undertake to update
these forward-looking statements.
Media Contact: Carrie Yamond Mas 917-371-2320
cmas@eksobionics.com
Investor Contact: David Carey 212-867-1768
investors@eksobionics.com
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Apr 2023 to Apr 2024